Celldex Therapeutics, Inc.
CLDX
$30.16
$1.625.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 518.57M | 583.22M | 630.34M | 673.29M | 725.28M |
| Total Receivables | 2.02M | 90.00K | 90.00K | 1.06M | 700.00K |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 14.08M | 21.03M | 17.98M | 19.40M | 21.18M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 534.66M | 604.34M | 648.40M | 693.76M | 747.16M |
|
|
|||||
| Total Current Assets | 534.66M | 604.34M | 648.40M | 693.76M | 747.16M |
| Net Property, Plant & Equipment | 7.77M | 7.55M | 7.51M | 8.12M | 8.24M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 13.36M | 9.36M | 9.30M | 10.41M | 9.75M |
| Total Assets | 582.98M | 648.44M | 692.41M | 739.47M | 792.34M |
|
|
|||||
| Total Accounts Payable | 1.18M | 4.27M | 2.07M | 3.41M | 3.27M |
| Total Accrued Expenses | 47.03M | 39.72M | 28.42M | 25.46M | 33.84M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 1.55M | 1.55M | 1.54M | 1.50M | 1.45M |
| Total Finance Division Other Current Liabilities | 1.23M | 930.00K | 930.00K | 1.65M | 942.00K |
| Total Other Current Liabilities | 1.23M | 930.00K | 930.00K | 1.65M | 942.00K |
| Total Current Liabilities | 50.99M | 46.47M | 32.96M | 32.02M | 39.50M |
|
|
|||||
| Total Current Liabilities | 50.99M | 46.47M | 32.96M | 32.02M | 39.50M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 784.00K | 1.07M | 1.50M | 1.93M | 2.36M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 4.04M | 2.54M | 2.54M | 2.54M | 3.47M |
| Total Liabilities | 55.82M | 50.08M | 37.00M | 36.49M | 45.34M |
|
|
|||||
| Common Stock & APIC | 2.34B | 2.33B | 2.32B | 2.31B | 2.30B |
| Retained Earnings | -1.81B | -1.73B | -1.67B | -1.61B | -1.56B |
| Treasury Stock & Other | 3.63M | 3.77M | 3.34M | 3.57M | 3.31M |
| Total Common Equity | 527.17M | 598.36M | 655.41M | 702.98M | 747.01M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 527.17M | 598.36M | 655.41M | 702.98M | 747.01M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 527.17M | 598.36M | 655.41M | 702.98M | 747.01M |
|
|
|||||